// App-Quantinova.ai

e13009 : Cardiac function in patients receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer in routine practice.

Researchers

Presenter

  • JAMAL ZEKRI

Principal Investigators

  • Haleem J. Rasool

  • Syed Azhar J Rizvi

  • Ehab Mosaad Abdel Ghany Mahmoud

  • Ayman Ahamd Rasmy

  • Aboelkhair Al-Gahmi

  • Kamel Farag

Medical Centers

  • College of Medicine, Alfaisal University, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia

  • Milton Keynes Hospital NHS Trust, Milton Keynes, United Kingdom

  • National Cancer Institute, Cairo University, Cairo, Egypt, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

  • Medical Oncology, Zagazig University Hospitals, Zagazig, Egypt

  • Medical Oncology-King Saud Medical City, Riyadh, Saudi Arabia

  • King Abdulaziz Medical City, Riyadh, Saudi Arabia

  • Mansoura Oncology Center Mansoura University, Mansoura, Egypt

Locations

  • Saudi Arabia

  • United Kingdom

  • Egypt

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved